. 2017 Jul 18;8:480. doi: 10.3389/fphys.2017.00480

Table 3.

Correlation between the SHI and clinicopathologic characteristics.

Clinical characteristics	Training cohort				Validation cohort
		SHI ≤ 2.84 (N = 19)	SHI > 2.84 (N = 169)	P	SHI ≤ 2.84 (N = 13)	SHI > 2.84 (N = 164)	P
Age	≤ 50	7	62	1.000	7	61	0.250
	>50	12	107		6	103
Sex	Female	4	22	0.307^a	1	31	0.468^a
	Male	15	147		12	133
AFP, ng/mL	≤ 400	11	128	0.104	7	123	0.110
	>400	8	41		6	41
ALT, U/L	≤ 75	19	158	0.607^a	9	90	0.392^a
	>75	0	11		4	74
HBsAg	Negative	1	21	0.704^a	0	21	0.370^a
	Positive	18	148		13	143
Liver cirrhosis	No	5	35	0.561	2	41	0.737^a
	Yes	14	134		11	123
No. of tumor	Single	18	133	0.130^a	10	138	0.450^a
	Multiple	1	36		3	26
Tumor size, cm	≤ 5	9	110	0.139	6	101	0.378
	>5	10	59		7	63
Tumor encapsulation	Complete	9	105	0.225	11	110	0.232^a
	None	10	64		2	54
Satellite lesion	No	17	148	1.000^a	12	149	1.000^a
	Yes	2	21		1	15
Vascular invasion	No	10	108	0.453	4	100	0.042^a
	Yes	9	61		9	64
Tumor differentation	I–II	11	105	0.805	7	107	0.548
	III–IV	8	64		6	57
Child-Pugh score	A	16	161	0.086^a	11	148	0.625^a
	B	3	8		2	16
BCLC stage	0+A	16	121	0.289^a	8	131	0.156
	B+C	3	48		5	33

AFP, α-fetoprotein; ALT, alanine aminotransferase; HBsAg, hepatitis B surface antigen; BCLC, Barcelona Clinic Liver Cancer; SLI, systemic hepatic-damage index.

Fisher exact test. Bold value represents significant (P < 0.05).